Tag: autumn booster programme

Covid: UK is first country to approve dual-strain vaccine

The UK has become the first country to approve a dual vaccine which tackles both the original Covid virus and the newer Omicron variant. The vaccine will now be part of the autumn booster campaign.

The Joint Committee on Vaccination and Immunisation (JCVI) has published its advice on which vaccines should be used in this year’s autumn booster programme.

All of the available boosters provide good protection against severe illness from COVID-19 and the Committee has emphasised that getting a booster in good time before the winter season is more important for those eligible than the type of vaccine that is received.

The vaccines advised for use in the autumn booster programme are:

For adults aged 18 years and above:

  • Moderna mRNA (Spikevax) bivalent Omicron BA.1/Original ‘wild-type’ vaccine
  • Moderna mRNA (Spikevax) Original ‘wild-type’ vaccine
  • Pfizer-BioNTech mRNA (Comirnaty) Original ‘wild-type’ vaccine
  • in exceptional circumstances, the Novavax Matrix-M adjuvanted wild-type vaccine (Nuvaxovid) may be used when no alternative clinically suitable UK-approved COVID-19 vaccine is available

For people aged 12 to 17 years:

  • Pfizer-BioNTech mRNA (Comirnaty) Original ‘wild-type’ vaccine

For people aged 5 to 11 years:

  • Pfizer-BioNTech mRNA (Comirnaty) Original ‘wild-type’ vaccine paediatric formulation

‘Bivalent’ vaccines have been developed by global manufacturers since the emergence and dominance of the Omicron variant. These vaccines contain two different antigens (substances that induce an immune response) based on two different COVID-19 strains, or variants. The original mRNA vaccines contain one antigen (monovalent), based on the original ‘wild-type’ strain.

Studies indicate the Moderna bivalent vaccine produces a marginally higher immune response against some variants than the Moderna mRNA Original ‘wild-type’ vaccine. The clinical relevance of these small differences is uncertain.

The committee will consider further bivalent vaccines for use in the programme as they are approved by the MHRA.

In its latest advice the JCVI has stated that, where feasible, it would be preferable for a single type of booster vaccine to be offered throughout the duration of the autumn programme for simplicity of deployment.

Professor Wei Shen Lim, Chair of COVID-19 immunisation on the JCVI, said: “All of the available booster vaccines offer very good protection against severe illness from COVID-19. As more vaccines continue to be developed and approved, the JCVI will consider the benefits of including them in the UK programme.

“It is important that everyone who is eligible takes up a booster this autumn, whichever vaccine is on offer. This will increase your protection against being severely ill from COVID-19 as we move into winter.”

Dr Mary Ramsay, Head of Immunisation at UKHSA, said: “Although cases of COVID-19 are relatively low at present, we are expecting to see the virus circulating more widely during the winter months.

“The booster is being offered to those at higher risk of severe illness and by taking up the booster vaccine this autumn, you will increase your protection ahead of the winter months, when respiratory viruses are typically at their peak.”

JCVI provides interim advice on an autumn COVID-19 booster programme

The Joint Committee on Vaccination and Immunisation (JCVI) has provided interim advice to the UK government regarding coronavirus (COVID-19) booster doses this autumn.

The boosters would be for more vulnerable adults, alongside frontline social care and health workers, in order to maintain their protection over the winter against severe COVID-19.

The advice should be considered as interim and for the purposes of operational planning for the autumn for the NHS, care homes and wider health community.

The committee recognises that there is considerable uncertainty with regards to the likelihood, timing and severity of any potential future wave of COVID-19 in the UK in the year ahead.

Despite these uncertainties, winter will remain the season when the threat from COVID-19 is greatest for individuals and for health communities.

As in autumn 2021, the primary objective of the 2022 autumn booster programme will be to increase population immunity and protection against severe COVID-19 disease, specifically hospitalisation and death, over the winter period.

The JCVI’s current view is that in autumn 2022, a COVID-19 vaccine should be offered to:

  • residents in a care home for older adults and staff
  • frontline health and social care workers
  • all those 65 years of age and over
  • adults aged 16 to 64 years who are in a clinical risk group

Professor Wei Shen Lim, Chair of COVID-19 vaccination on the JCVI, said: “Last year’s autumn booster vaccination programme provided excellent protection against severe COVID-19, including against the Omicron variant.

“We have provided interim advice on an autumn booster programme for 2022 so that the NHS and care homes are able to start the necessary operational planning, to enable high levels of protection for more vulnerable individuals and frontline healthcare staff over next winter.

“As we continue to review the scientific data, further updates to this advice will follow.”

Throughout the pandemic, evidence has clearly shown that COVID-19 has disproportionately affected those in older age groups, residents in care homes for older adults, and those with certain underlying health conditions, particularly those who are severely immunosuppressed.

It is important that those who are eligible for the spring booster currently being rolled out – specifically adults aged 75 years and over, residents in a care home for older adults, and individuals aged 12 years and over who are immunosuppressed – still come forward to ensure they are protected.

The JCVI will continue its on-going review of the vaccination programme and the epidemiological situation, particularly in relation to the timing and value of doses for less vulnerable older adults and those in clinical risk groups ahead of autumn 2022.

The committee will announce its final plans for the autumn programme, including further detail on the definitions of clinical risk groups, in due course.